HeimCLIFF • OTCMKTS
add
Cordlife Group Ltd
Við síðustu lokun
0,070 $
Árabil
0,069 $ - 0,17 $
Markaðsvirði
47,08 m. SGD
Meðalmagn
72,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
SGX
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (SGD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 9,46 m. | 13,52% |
Rekstrarkostnaður | 10,41 m. | 1,84% |
Nettótekjur | -5,55 m. | -11,80% |
Hagnaðarhlutfall | -58,72 | 1,51% |
Hagnaður á hvern hlut | — | — |
EBITDA | -4,29 m. | 19,64% |
Virkt skatthlutfall | -29,22% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (SGD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 51,77 m. | -15,32% |
Heildareignir | 201,76 m. | -7,08% |
Heildarskuldir | 97,28 m. | -1,42% |
Eigið fé alls | 104,48 m. | — |
Útistandandi hlutabréf | 256,31 m. | — |
Eiginfjárgengi | 0,17 | — |
Arðsemi eigna | -6,12% | — |
Ávöxtun eigin fjár | -11,53% | — |
Peningaflæði
Breyting á handbæru fé
| (SGD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -5,55 m. | -11,80% |
Handbært fé frá rekstri | -751,00 þ. | -1.606,82% |
Reiðufé frá fjárfestingum | -6,59 m. | 50,34% |
Reiðufé frá fjármögnun | -557,00 þ. | -106,95% |
Breyting á handbæru fé | -8,36 m. | -45,26% |
Frjálst peningaflæði | -894,00 þ. | — |
Um
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Framkvæmdastjóri
Stofnsett
2. maí 2001
Vefsvæði
Starfsfólk
111
